Literature DB >> 31332613

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Yoshihiro Nishida1,2, Akira Kawai3, Junya Toguchida4, Akira Ogose5, Keisuke Ae6, Toshiyuki Kunisada7, Yoshihiro Matsumoto8, Tomoya Matsunobu9, Kunihiko Takahashi10, Kazuki Nishida10, Toshifumi Ozaki11.   

Abstract

BACKGROUND: Treatment modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative treatment. In this study, tumor characteristics of DF, transition of the treatment modality, and clinical outcome of surgical treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan.
METHODS: Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical treatment.
RESULTS: The number of registered patients increased gradually. The frequency of surgical treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34).
CONCLUSIONS: The treatment modality has shifted from surgical to conservative treatment, with risk factors for surgical treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.

Entities:  

Keywords:  Desmoid-type fibromatosis; Marginal resection; Registry; Treatment modality

Mesh:

Year:  2019        PMID: 31332613     DOI: 10.1007/s10147-019-01512-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  39 in total

1.  Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.

Authors:  M T Ballo; G K Zagars; A Pollack; P W Pisters; R A Pollack
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: 
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Extremity and trunk desmoid tumors: a multifactorial analysis of outcome.

Authors:  N B Merchant; J J Lewis; J M Woodruff; D H Leung; M F Brennan
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

4.  Statistics of bone sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan.

Authors:  Koichi Ogura; Takahiro Higashi; Akira Kawai
Journal:  J Orthop Sci       Date:  2016-11-12       Impact factor: 1.601

5.  Optimizing treatment of desmoid tumors.

Authors:  Dina Lev; Dhanasekaran Kotilingam; Caimiao Wei; Matthew T Ballo; Gunar K Zagars; Peter W T Pisters; Alexander A Lazar; Shreyaskumar R Patel; Robert S Benjamin; Raphael E Pollock
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Authors:  Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2012-12-31       Impact factor: 3.167

7.  High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.

Authors:  Anika Hansmann; Claudia Adolph; Tilmann Vogel; Andreas Unger; Gabriela Moeslein
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

8.  CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.

Authors:  Shunsuke Hamada; Naohisa Futamura; Kunihiro Ikuta; Hiroshi Urakawa; Eiji Kozawa; Naoki Ishiguro; Yoshihiro Nishida
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 9.  UK guidelines for the management of soft tissue sarcomas.

Authors:  Adam Dangoor; Beatrice Seddon; Craig Gerrand; Robert Grimer; Jeremy Whelan; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2016-11-15

10.  Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Yoji Shido; Hiroshi Urakawa; Eisuke Arai; Naoki Ishiguro
Journal:  Cancers (Basel)       Date:  2012-02-07       Impact factor: 6.639

View more
  2 in total

1.  Less-invasive fascia-preserving surgery for abdominal wall desmoid.

Authors:  Yoshihiro Nishida; Shunsuke Hamada; Tomohisa Sakai; Kan Ito; Kunihiro Ikuta; Hiroshi Urakawa; Hiroshi Koike; Shiro Imagama
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

2.  A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors.

Authors:  Toshihiko Doi; Yasutoshi Kuboki; Yoichi Naito; Masahiro Ishida; Tetsuya Tanaka; Yoshito Takeuchi
Journal:  Cancer Sci       Date:  2022-01-13       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.